Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

BACKGROUND: The safety and immunogenicity of SAAVI DNA-C2 (4 mg IM), SAAVI MVA-C (2.9 x 10(9) pfu IM) and Novartis V2-deleted subtype C gp140 (100 mcg) with MF59 adjuvant in various vaccination regimens was evaluated in HIV-uninfected adults in South Africa. METHODS: Participants at three South Afri...

Descripción completa

Detalles Bibliográficos
Autores principales: Churchyard, Gavin, Mlisana, Koleka, Karuna, Shelly, Williamson, Anna-Lise, Williamson, Carolyn, Morris, Lynn, Tomaras, Georgia D., De Rosa, Stephen C., Gilbert, Peter B., Gu, Niya, Yu, Chenchen, Mkhize, Nonhlanhla N., Hermanus, Tandile, Allen, Mary, Pensiero, Michael, Barnett, Susan W., Gray, Glenda, Bekker, Linda-Gail, Montefiori, David C., Kublin, James, Corey, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008759/
https://www.ncbi.nlm.nih.gov/pubmed/27583368
http://dx.doi.org/10.1371/journal.pone.0161753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008759/
https://www.ncbi.nlm.nih.gov/pubmed/27583368
http://dx.doi.org/10.1371/journal.pone.0161753

Ejemplares similares